Profile data is unavailable for this security.
About the company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
- Revenue in USD (TTM)23.29bn
- Net income in USD5.17bn
- Incorporated1933
- Employees23.30k
- LocationBristol-Myers Squibb Co430 E 29th St Fl 14NEW YORK 10016-8367United StatesUSA
- Phone+1 (212) 546-4000
- Fax+1 (302) 655-5049
- Websitehttps://www.bms.com/
More ▼
Mergers & acquisitions
| Acquired company | BMY:NYQ since announced | Transaction value |
|---|---|---|
| Celgene Corp | -12.56% | 79.38bn |
Data delayed at least 15 minutes, as of Jun 26 2019 14:33 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan plc | 15.71bn | -7.23bn | 40.08bn | 16.90k | -- | 0.6174 | -- | 2.42 | -21.63 | -21.59 | 46.72 | 187.74 | 0.1496 | 2.29 | 5.85 | 929,727.80 | -6.88 | -3.61 | -7.40 | -3.89 | 86.22 | 83.23 | -45.98 | -28.24 | 0.6041 | 0.6508 | 0.2765 | -- | -0.9617 | 43.41 | 24.17 | -- | -3.81 | -- |
| Vertex Pharmaceuticals Incorporated | 3.27bn | 594.86m | 43.70bn | 2.50k | 74.43 | 9.24 | 66.90 | 13.35 | 2.29 | 8.29 | 12.57 | 18.43 | 0.6222 | 3.41 | 8.53 | 1,306,093.00 | 10.83 | -5.11 | 13.32 | -6.65 | 86.74 | 88.18 | 17.41 | -8.99 | 3.66 | 40.52 | 0.1061 | -- | 22.46 | 20.25 | 103.80 | -- | 13.20 | -- |
| Biogen Inc | 13.81bn | 4.69bn | 44.68bn | 7.80k | 9.76 | 3.21 | 7.56 | 3.20 | 23.33 | 23.21 | 68.51 | 70.85 | 0.5258 | 2.37 | 5.41 | 1,770,718.00 | 18.14 | 18.80 | 20.60 | 21.92 | 85.72 | 87.27 | 34.49 | 32.27 | 2.60 | -- | 0.3007 | 0.00 | 9.61 | 14.18 | 19.98 | 19.05 | -24.06 | -- |
| Zoetis Inc | 5.91bn | 1.35bn | 53.34bn | 10.00k | 39.97 | 22.91 | 31.40 | 8.97 | 2.77 | 2.86 | 12.19 | 4.84 | 0.6043 | 1.40 | 6.18 | 591,400.00 | 13.72 | 10.65 | 15.37 | 12.75 | 66.93 | 66.05 | 22.71 | 16.42 | 2.79 | 8.99 | 0.7355 | 23.63 | 9.76 | 5.01 | 28.53 | 22.37 | 12.93 | 20.91 |
| Celgene Corporation | 15.77bn | 4.70bn | 68.10bn | 8.85k | 14.80 | 8.32 | 12.68 | 4.32 | 6.52 | 6.58 | 21.85 | 11.58 | 0.4368 | 1.21 | 7.30 | 1,781,292.00 | 13.03 | 10.88 | 14.44 | 12.12 | 96.25 | 95.94 | 29.82 | 24.47 | 2.66 | 6.58 | 0.713 | 0.00 | 17.52 | 18.67 | -4.89 | 22.52 | 18.86 | -- |
| Bristol-Myers Squibb Co | 23.29bn | 5.17bn | 77.91bn | 23.30k | 15.06 | 5.11 | 13.14 | 3.34 | 3.16 | 3.14 | 14.23 | 9.30 | 0.6858 | 5.35 | 5.19 | 999,485.00 | 15.29 | 10.05 | 21.08 | 13.92 | 71.13 | 73.87 | 22.29 | 17.90 | 1.79 | 28.85 | 0.282 | 74.94 | 8.59 | 6.61 | 27.49 | 14.19 | 12.11 | 2.71 |
| Gilead Sciences, Inc. | 22.32bn | 5.90bn | 84.91bn | 11.00k | 14.62 | 3.85 | 11.52 | 3.78 | 4.54 | 4.54 | 17.20 | 17.23 | 0.3482 | 5.39 | 6.32 | 2,029,091.00 | 9.19 | 23.08 | 10.92 | 28.22 | 78.45 | 84.37 | 26.40 | 43.52 | 3.53 | 10.79 | 0.5461 | 17.01 | -15.24 | 14.59 | -46.06 | 12.17 | 37.10 | -- |
| Amgen, Inc. | 23.75bn | 8.08bn | 107.10bn | 21.50k | 14.05 | 9.99 | 10.69 | 4.52 | 12.53 | 12.53 | 36.88 | 17.63 | 0.3514 | 1.41 | 6.42 | 1,104,651.00 | 11.95 | 9.96 | 14.42 | 11.42 | 82.27 | 81.15 | 34.00 | 32.60 | 2.53 | 13.02 | 0.753 | 40.32 | 3.93 | 4.92 | 3.90 | 10.56 | 1.27 | 22.94 |
| Eli Lilly And Co | 23.95bn | 2.75bn | 111.88bn | 38.68k | 41.21 | 43.74 | 25.28 | 4.53 | 2.71 | 6.28 | 23.58 | 2.55 | 0.5815 | 1.56 | 4.95 | 619,128.80 | 6.68 | 6.48 | 9.26 | 9.00 | 74.96 | 74.01 | 11.49 | 11.69 | 0.8493 | 29.72 | 0.8616 | 87.08 | 7.36 | 1.22 | 99.27 | -6.17 | 22.52 | 2.80 |
| AbbVie Inc | 32.65bn | 5.42bn | 116.15bn | 30.00k | 22.25 | -- | 15.99 | 3.56 | 3.54 | 3.48 | 21.58 | -5.29 | 0.5178 | 4.31 | 5.67 | 1,088,233.00 | 8.64 | 9.30 | 11.45 | 12.12 | 77.31 | 77.24 | 16.68 | 18.82 | 0.9142 | 5.26 | 1.27 | 83.76 | 16.08 | 11.75 | 1.06 | 6.83 | 5.38 | 17.54 |
Data as of Jun 26 2019. Currency figures normalised to Bristol-Myers Squibb Co's reporting currency: US Dollar USD
34.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2019 | 130.17m | 7.96% |
| Wellington Management Co. LLPas of 08 May 2019 | 121.15m | 7.41% |
| BlackRock Fund Advisorsas of 31 Mar 2019 | 72.54m | 4.43% |
| SSgA Funds Management, Inc.as of 31 Mar 2019 | 68.91m | 4.21% |
| Dodge & Coxas of 31 Mar 2019 | 43.15m | 2.64% |
| Fidelity Management & Research Co.as of 31 Mar 2019 | 34.52m | 2.11% |
| Columbia Management Investment Advisers LLCas of 31 Mar 2019 | 26.53m | 1.62% |
| Geode Capital Management LLCas of 31 Mar 2019 | 24.16m | 1.48% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2019 | 22.54m | 1.38% |
| PRIMECAP Management Co.as of 31 Mar 2019 | 21.75m | 1.33% |
More ▼
Data from 31 Mar 2019 - 31 Mar 2019Source: FactSet Research Systems Inc.
